BFM
ACHL

Boothbay Fund Management’s Achilles Therapeutics ACHL Stock Holding History

Boothbay Fund Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-418,441
Closed -$477K – 1881
2024
Q4 		$477K Sell
418,441
-2,040
-0.5% -$2.1K 0.01% 893
2024
Q3 		$429K Hold
420,481
– – 0.01% 1044
2024
Q2 		$343K Hold
420,481
– – 0.01% 1113
2024
Q1 		$526K Buy
+420,481
New +$454K 0.01% 984

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Boothbay Fund Management's ACHL Position: Q1 2025 in Review

Boothbay Fund Management sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 418,441 shares — an estimated $477K sold.

Boothbay Fund Management first reported a position in ACHL in Q1 2024 and held it in 4 quarters. The position peaked at $526K in Q1 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Boothbay Fund Management reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 418,441 Achilles Therapeutics shares in Q1 2025, an estimated $477K.
  • Boothbay Fund Management first reported a position in Achilles Therapeutics in Q1 2024 and held it in 4 quarters.
  • Boothbay Fund Management's Achilles Therapeutics position peaked at $526K in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.